JP2019502371A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019502371A5 JP2019502371A5 JP2018526190A JP2018526190A JP2019502371A5 JP 2019502371 A5 JP2019502371 A5 JP 2019502371A5 JP 2018526190 A JP2018526190 A JP 2018526190A JP 2018526190 A JP2018526190 A JP 2018526190A JP 2019502371 A5 JP2019502371 A5 JP 2019502371A5
- Authority
- JP
- Japan
- Prior art keywords
- ortholog
- cmv
- active
- protein
- mir
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000701022 Cytomegalovirus Species 0.000 claims description 72
- 239000013598 vector Substances 0.000 claims description 59
- 239000000427 antigen Substances 0.000 claims description 33
- 108091007433 antigens Proteins 0.000 claims description 33
- 102000036639 antigens Human genes 0.000 claims description 33
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 15
- 150000007523 nucleic acids Chemical group 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 101150016730 UL79 gene Proteins 0.000 claims description 11
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 101150088910 UL82 gene Proteins 0.000 claims description 9
- 244000052769 pathogen Species 0.000 claims description 8
- 230000001717 pathogenic effect Effects 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 6
- 108091008874 T cell receptors Proteins 0.000 claims description 6
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 6
- 239000002679 microRNA Substances 0.000 claims description 6
- 108700011259 MicroRNAs Proteins 0.000 claims description 5
- 230000005867 T cell response Effects 0.000 claims description 5
- 210000004027 cell Anatomy 0.000 claims description 5
- 230000028993 immune response Effects 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 3
- 108091008875 B cell receptors Proteins 0.000 claims description 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 3
- 208000021309 Germ cell tumor Diseases 0.000 claims description 3
- 241000711549 Hepacivirus C Species 0.000 claims description 3
- 241000700721 Hepatitis B virus Species 0.000 claims description 3
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 3
- 241000282560 Macaca mulatta Species 0.000 claims description 3
- 108091028080 MiR-132 Proteins 0.000 claims description 3
- 108091033773 MiR-155 Proteins 0.000 claims description 3
- 108091062140 Mir-223 Proteins 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 3
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 3
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 3
- 241001631646 Papillomaviridae Species 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 3
- 241000713311 Simian immunodeficiency virus Species 0.000 claims description 3
- 241000700584 Simplexvirus Species 0.000 claims description 3
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 3
- 238000007918 intramuscular administration Methods 0.000 claims description 3
- 238000007912 intraperitoneal administration Methods 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 108091064282 miR-125 stem-loop Proteins 0.000 claims description 3
- 108091037066 miR-125-1 stem-loop Proteins 0.000 claims description 3
- 108091062107 miR-125-2 stem-loop Proteins 0.000 claims description 3
- 108091079767 miR-125-3 stem-loop Proteins 0.000 claims description 3
- 108091079658 miR-142-1 stem-loop Proteins 0.000 claims description 3
- 108091071830 miR-142-2 stem-loop Proteins 0.000 claims description 3
- 108091032320 miR-146 stem-loop Proteins 0.000 claims description 3
- 108091024530 miR-146a stem-loop Proteins 0.000 claims description 3
- 108091062762 miR-21 stem-loop Proteins 0.000 claims description 3
- 108091041631 miR-21-1 stem-loop Proteins 0.000 claims description 3
- 108091044442 miR-21-2 stem-loop Proteins 0.000 claims description 3
- -1 miR-27a Proteins 0.000 claims description 3
- 108091050734 miR-652 stem-loop Proteins 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 claims description 3
- 108700028369 Alleles Proteins 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 201000004792 malaria Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 244000045947 parasite Species 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 238000012045 magnetic resonance elastography Methods 0.000 claims 4
- 108091070501 miRNA Proteins 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 17
- 101150085955 US11 gene Proteins 0.000 description 10
- 230000030279 gene silencing Effects 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022135565A JP2022174123A (ja) | 2015-11-20 | 2022-08-29 | マイクロｒｎａ認識エレメントを含むｃｍｖベクター |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562258393P | 2015-11-20 | 2015-11-20 | |
| US62/258,393 | 2015-11-20 | ||
| US201662365259P | 2016-07-21 | 2016-07-21 | |
| US62/365,259 | 2016-07-21 | ||
| PCT/US2016/062973 WO2017087921A1 (en) | 2015-11-20 | 2016-11-20 | Cmv vectors comprising microrna recognition elements |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022135565A Division JP2022174123A (ja) | 2015-11-20 | 2022-08-29 | マイクロｒｎａ認識エレメントを含むｃｍｖベクター |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019502371A JP2019502371A (ja) | 2019-01-31 |
| JP2019502371A5 true JP2019502371A5 (enExample) | 2019-12-26 |
| JP7133468B2 JP7133468B2 (ja) | 2022-09-08 |
Family
ID=58719315
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018526190A Active JP7133468B2 (ja) | 2015-11-20 | 2016-11-20 | マイクロｒｎａ認識エレメントを含むｃｍｖベクター |
| JP2022135565A Pending JP2022174123A (ja) | 2015-11-20 | 2022-08-29 | マイクロｒｎａ認識エレメントを含むｃｍｖベクター |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022135565A Pending JP2022174123A (ja) | 2015-11-20 | 2022-08-29 | マイクロｒｎａ認識エレメントを含むｃｍｖベクター |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10688164B2 (enExample) |
| EP (1) | EP3377636A4 (enExample) |
| JP (2) | JP7133468B2 (enExample) |
| CN (2) | CN108474003A (enExample) |
| AU (1) | AU2016355468B2 (enExample) |
| CA (1) | CA3005136A1 (enExample) |
| MA (1) | MA43285A (enExample) |
| WO (1) | WO2017087921A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR201802741T4 (tr) | 2010-05-14 | 2018-03-21 | Univ Oregon Health & Science | Rekombinant hcmv ve rhcmv vektörleri ve bunların kullanımları. |
| PT2691530T (pt) | 2011-06-10 | 2018-05-10 | Univ Oregon Health & Science | Glicoproteínas e vectores recombinantes cmv |
| AU2014225886B2 (en) | 2013-03-05 | 2020-04-16 | Oregon Health & Science University | Cytomegalovirus vectors enabling control of T cell targeting |
| CN113528466B (zh) | 2014-07-16 | 2024-12-24 | 俄勒冈健康与科学大学 | 包含外源抗原的人巨细胞病毒 |
| SG11201706454VA (en) | 2015-02-10 | 2017-09-28 | Univ Oregon Health & Science | Methods and compositions useful in generating non canonical cd8+ t cell responses |
| CN108474003A (zh) | 2015-11-20 | 2018-08-31 | 俄勒冈健康与科学大学 | 包含微小rna识别元件的cmv载体 |
| EP3474889A4 (en) | 2016-06-22 | 2020-04-29 | International AIDS Vaccine Initiative, Inc. | RECOMBINANT CYTOMEGALOVIRUS VECTORS FOR USE AS TUBERCULOSIS VACCINES |
| BR112019007982A2 (pt) | 2016-10-18 | 2019-07-02 | Univ Oregon Health & Science | vetores de citomegalovírus elicitando células t restringidas por moléculas do complexo de histocompatibilidade e principal |
| GB201714430D0 (en) * | 2017-09-07 | 2017-10-25 | Micol Romain | Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue |
| WO2019079155A1 (en) | 2017-10-17 | 2019-04-25 | International Aids Vaccine Initiative, Inc. | CASSETTES OF ANTIGENS OF TUBERCULOSIS |
| JP2022536122A (ja) * | 2019-06-07 | 2022-08-12 | オレゴン ヘルス アンド サイエンス ユニバーシティ | 腫瘍関連抗原特異的ｔ細胞応答 |
| PH12022550439A1 (en) | 2019-08-20 | 2023-03-13 | Univ Oregon Health & Science | Modulation of t cell responses by ul18 of human cytomegalovirus |
| IL295724A (en) | 2020-02-21 | 2022-10-01 | Combined Therapeutics Inc | Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids |
| KR20240049807A (ko) | 2021-08-31 | 2024-04-17 | 비르 바이오테크놀로지, 인코포레이티드 | 재조합 hcmv 벡터 및 이의 용도 |
| TW202328167A (zh) | 2021-08-31 | 2023-07-16 | 美商維爾生物科技股份有限公司 | 結核病疫苗 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US5273876A (en) | 1987-06-26 | 1993-12-28 | Syntro Corporation | Recombinant human cytomegalovirus containing foreign gene |
| DE3853139T2 (de) | 1987-06-26 | 1995-06-14 | Syntro Corp | Rekombinanter, fremde gene enthaltender menschlicher cytomegalovirus und seine verwendung. |
| WO1992003456A1 (en) * | 1990-08-16 | 1992-03-05 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating the effects of cytomegalovirus infections |
| SG49046A1 (en) | 1991-07-05 | 1998-05-18 | American Cyanamid Co | Method for identifying non-essential genes of the human cytomegalovirus genome and for screening for inhibitors of human cytomegaloverirus |
| AU7192394A (en) | 1993-07-19 | 1995-02-20 | Cantab Pharmaceuticals Research Limited | Production method for preparation of disabled viruses |
| DE69535125T2 (de) | 1994-04-29 | 2007-08-30 | Pharmacia & Upjohn Co. Llc, Kalamazoo | Impfstoff gegen felines immunodefizienz-virus |
| US5846806A (en) | 1994-07-29 | 1998-12-08 | American Cyanamid Company | Identification of a human cytomegalovirus gene region involved in down-regulation of MHC class I heavy chain expression |
| WO1996026267A1 (en) | 1995-02-21 | 1996-08-29 | Cantab Pharmaceuticals Research Limited | Viral preparations, vectors, immunogens, and vaccines |
| EP0820311A4 (en) | 1995-04-04 | 2002-09-25 | Cell Genesys Inc | TRANSPLANTATION OF GENETICALLY MODIFIED CELLS WITH LOW CLASS I PROTEIN RATES OF THE MAJOR HISTOCOMPATIBILITY COMPLEX ON THEIR SURFACE |
| EP0966301B1 (en) | 1996-07-31 | 2005-02-09 | Ortho-McNeil Pharmaceutical, Inc. | Identification of human cytomegalovirus genes involved in down-regulation of mhc class i heavy chain expression |
| US20030138454A1 (en) | 1997-06-09 | 2003-07-24 | Oxxon Pharmaccines, Ltd. | Vaccination method |
| DE19733364A1 (de) | 1997-08-01 | 1999-02-04 | Koszinowski Ulrich H Prof | Verfahren zur Klonierung eines großen Virusgenoms |
| AU3910097A (en) | 1997-08-05 | 1999-03-01 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Live recombinant vaccine comprising inefficiently or non-replicating vir us |
| US6884785B2 (en) * | 1999-06-17 | 2005-04-26 | The Scripps Research Institute | Compositions and methods for the treatment or prevention of autoimmune diabetes |
| US7204990B1 (en) | 2000-11-28 | 2007-04-17 | Medimmune Vaccines, Inc. | Attenuation of cytomegalovirus virulence |
| AU2002242085A1 (en) | 2001-02-02 | 2002-08-19 | Chemocentryx, Inc. | Methods and compositions useful for stimulating an immune response |
| WO2002066629A2 (en) | 2001-02-21 | 2002-08-29 | Gabriele Hahn | Recombinant vector containing infectious human cytomegalovirus genome with preserved wild-type characteristics of clinical isolates |
| GB0122232D0 (en) | 2001-09-14 | 2001-11-07 | Medical Res Council | Gene expression |
| JP4601956B2 (ja) | 2001-09-20 | 2010-12-22 | グラクソ グループ リミテッド | Ｈｉｖ−ｇａｇのコドン最適化ｄｎａワクチン |
| US20030118568A1 (en) | 2001-12-18 | 2003-06-26 | Board Of Trustees Of The University Of Arkansas | Viral stealth technology to prevent T cell-mediated rejection of xenografts |
| JP2005523942A (ja) | 2002-04-30 | 2005-08-11 | アヴィオル セラピューティクス インコーポレイテッド | 免疫療法のためのアデノウイルスベクター |
| DE10232322A1 (de) | 2002-07-16 | 2004-07-29 | Hahn, Gabriele, Dr. | Viral kodierte CxC determinieren den Gewebetropismus von HCMV |
| WO2005012545A2 (en) * | 2003-07-25 | 2005-02-10 | The Regents Of The University Of California | Cytomegalovirus gene function and methods for developing antivirals, anti-cmv vaccines, and cmv-based vectors |
| EP2497831B1 (en) | 2004-05-25 | 2014-07-16 | Oregon Health and Science University | TB vaccination using HCMV-based vaccine vectors |
| EP1602676A1 (en) | 2004-06-01 | 2005-12-07 | SOLVAY (Société Anonyme) | Catalytic compositions |
| EP1799255A4 (en) | 2004-06-25 | 2008-10-01 | Medimmune Vaccines Inc | RECOMBINANT HUMANESE CYTOMEGALOVIRUS AND HETEROLOGIST ANTIGENS CONTAINING VACCINES |
| WO2006125983A1 (en) | 2005-05-23 | 2006-11-30 | Oxxon Therapeutics Ltd | Compositions for inducing an immune response against hepatitis b |
| WO2007027860A2 (en) | 2005-08-31 | 2007-03-08 | Genvec, Inc. | Adenoviral vector-based malaria vaccines |
| WO2008112146A2 (en) | 2007-03-07 | 2008-09-18 | The Trustees Of The University Of Pennsylvania | 2d partially parallel imaging with k-space surrounding neighbors based data reconstruction |
| JP2010532764A (ja) | 2007-07-06 | 2010-10-14 | トゥルビオン・ファーマシューティカルズ・インコーポレーテッド | Ｃ末端に配置された特異的結合性ドメインを有する結合性ペプチド |
| CL2008003218A1 (es) | 2007-10-30 | 2009-03-06 | Genentech Inc | Método para la purificación de un anticuerpo a partir de una composición que comprende el anticuerpo y al menos un contaminante. |
| US8074351B2 (en) * | 2008-07-25 | 2011-12-13 | Panasonic Corporation | Part mounting device and part mounting method |
| JP2012519484A (ja) * | 2009-03-06 | 2012-08-30 | マウント・シナイ・スクール・オヴ・メディシン | マイクロｒｎａ応答要素を含む弱毒化生インフルエンザウイルスワクチン |
| JP5833565B2 (ja) | 2009-12-23 | 2015-12-16 | ４−アンティボディ・アクチェンゲゼルシャフト４−Ａｎｔｉｂｏｄｙ Ａｇ | ヒトサイトメガロウイルスに対する結合メンバー |
| CN102844663B (zh) | 2010-01-27 | 2016-01-06 | 俄勒冈健康科学大学 | 基于巨细胞病毒的免疫原性制剂 |
| CA2793959C (en) | 2010-03-25 | 2019-06-04 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
| SG185121A1 (en) | 2010-05-05 | 2012-11-29 | Christian Thirion | Vaccine against beta-herpesvirus infection and use thereof |
| TR201802741T4 (tr) | 2010-05-14 | 2018-03-21 | Univ Oregon Health & Science | Rekombinant hcmv ve rhcmv vektörleri ve bunların kullanımları. |
| PT2691530T (pt) | 2011-06-10 | 2018-05-10 | Univ Oregon Health & Science | Glicoproteínas e vectores recombinantes cmv |
| US20130156808A1 (en) | 2011-11-22 | 2013-06-20 | Stipan Jonjic | Vaccine comprising beta-herpesvirus |
| EP2909324B1 (en) * | 2012-10-25 | 2020-02-26 | Tocagen Inc. | Retroviral vector with mini-promoter cassette |
| US8903341B2 (en) | 2012-12-05 | 2014-12-02 | Qualcomm Incorporated | Successive interference cancellation (SIC) ordering algorithms for improved multiple-input multiple-output (MIMO) performance |
| AU2014225886B2 (en) | 2013-03-05 | 2020-04-16 | Oregon Health & Science University | Cytomegalovirus vectors enabling control of T cell targeting |
| CN113528466B (zh) | 2014-07-16 | 2024-12-24 | 俄勒冈健康与科学大学 | 包含外源抗原的人巨细胞病毒 |
| EP3048114A1 (en) | 2015-01-22 | 2016-07-27 | Novartis AG | Cytomegalovirus antigens and uses thereof |
| SG11201706454VA (en) | 2015-02-10 | 2017-09-28 | Univ Oregon Health & Science | Methods and compositions useful in generating non canonical cd8+ t cell responses |
| CN108474003A (zh) | 2015-11-20 | 2018-08-31 | 俄勒冈健康与科学大学 | 包含微小rna识别元件的cmv载体 |
| EP3474889A4 (en) | 2016-06-22 | 2020-04-29 | International AIDS Vaccine Initiative, Inc. | RECOMBINANT CYTOMEGALOVIRUS VECTORS FOR USE AS TUBERCULOSIS VACCINES |
| US20200182884A1 (en) | 2016-06-27 | 2020-06-11 | Juno Therapeutics, Inc. | Method of identifying peptide epitopes, molecules that bind such epitopes and related uses |
| BR112019007982A2 (pt) | 2016-10-18 | 2019-07-02 | Univ Oregon Health & Science | vetores de citomegalovírus elicitando células t restringidas por moléculas do complexo de histocompatibilidade e principal |
-
2016
- 2016-11-20 CN CN201680075638.9A patent/CN108474003A/zh active Pending
- 2016-11-20 CN CN202310470923.2A patent/CN116926128A/zh active Pending
- 2016-11-20 CA CA3005136A patent/CA3005136A1/en active Pending
- 2016-11-20 WO PCT/US2016/062973 patent/WO2017087921A1/en not_active Ceased
- 2016-11-20 MA MA043285A patent/MA43285A/fr unknown
- 2016-11-20 EP EP16867316.8A patent/EP3377636A4/en active Pending
- 2016-11-20 US US15/356,627 patent/US10688164B2/en active Active
- 2016-11-20 JP JP2018526190A patent/JP7133468B2/ja active Active
- 2016-11-20 AU AU2016355468A patent/AU2016355468B2/en not_active Ceased
-
2020
- 2020-05-08 US US16/870,766 patent/US20200368333A1/en not_active Abandoned
-
2022
- 2022-08-29 JP JP2022135565A patent/JP2022174123A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019502371A5 (enExample) | ||
| JP2019531745A5 (enExample) | ||
| Capone et al. | Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials | |
| Pastor et al. | An RNA toolbox for cancer immunotherapy | |
| Johansson et al. | Intradermal electroporation of naked replicon RNA elicits strong immune responses | |
| Kallen et al. | A novel, disruptive vaccination technology: self-adjuvanted RNActive® vaccines | |
| JP2018510650A5 (enExample) | ||
| Donnelly et al. | DNA vaccines: progress and challenges | |
| García-Arriaza et al. | Enhancing poxvirus vectors vaccine immunogenicity | |
| Kamphorst et al. | CD4 T-cell immunotherapy for chronic viral infections and cancer | |
| JP2019176869A5 (enExample) | ||
| JP2017522312A5 (enExample) | ||
| van de Wall et al. | Potent therapeutic efficacy of an alphavirus replicon DNA vaccine expressing human papilloma virus E6 and E7 antigens | |
| Zhou et al. | Cancer vaccines: current status and future directions | |
| JP2018509163A5 (enExample) | ||
| JP2017513478A5 (enExample) | ||
| CN110944675A (zh) | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 | |
| Lin et al. | Effector/memory but not naive regulatory T cells are responsible for the loss of concomitant tumor immunity | |
| JP2019502371A (ja) | マイクロｒｎａ認識エレメントを含むｃｍｖベクター | |
| Goyvaerts et al. | The journey of in vivo virus engineered dendritic cells from bench to bedside: a bumpy road | |
| Tenbusch et al. | Immunogenicity of DNA vaccines encoding simian immunodeficiency virus antigen targeted to dendritic cells in rhesus macaques | |
| WO2017161360A4 (en) | Multimodal vector for dendritic cell infection | |
| Assudani et al. | In vivo Expansion, Persistence, and Function of Peptide Vaccine–Induced CD8 T Cells Occur Independently of CD4 T Cells | |
| RU2021109510A (ru) | Вакцинация с использованием альфа 3 домена mica/b для лечения рака | |
| Freitas-Silva et al. | Dendritic cell-based approaches in the fight against diseases |